Log in

NASDAQ:EYEGEyegate Pharmaceuticals Stock Price, Forecast & News

$5.10
-0.06 (-1.16 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.04
Now: $5.10
$5.48
50-Day Range
$4.80
MA: $5.31
$5.89
52-Week Range
$2.25
Now: $5.10
$12.89
Volume108,462 shs
Average Volume29,564 shs
Market Capitalization$23.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.7
EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.
Read More
Eyegate Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEG
CUSIPN/A
Phone781-788-8869

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.69 million
Book Value$2.01 per share

Profitability

Net Income$-7,100,000.00

Miscellaneous

Employees11
Market Cap$23.61 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive EYEG News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter.

Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions

How has Eyegate Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eyegate Pharmaceuticals' stock was trading at $5.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EYEG shares have increased by 1.4% and is now trading at $5.10. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eyegate Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyegate Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eyegate Pharmaceuticals.

When is Eyegate Pharmaceuticals' next earnings date?

Eyegate Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Eyegate Pharmaceuticals.

How were Eyegate Pharmaceuticals' earnings last quarter?

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) released its earnings results on Wednesday, May, 6th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter. View Eyegate Pharmaceuticals' earnings history.

What price target have analysts set for EYEG?

1 Wall Street analysts have issued 1-year target prices for Eyegate Pharmaceuticals' shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Eyegate Pharmaceuticals' stock price to reach $12.00 in the next year. This suggests a possible upside of 135.3% from the stock's current price. View analysts' price targets for Eyegate Pharmaceuticals.

Has Eyegate Pharmaceuticals been receiving favorable news coverage?

News stories about EYEG stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eyegate Pharmaceuticals earned a coverage optimism score of -3.4 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutEyegate Pharmaceuticals.

Are investors shorting Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 15,100 shares, a decrease of 9.6% from the April 30th total of 16,700 shares. Based on an average daily volume of 81,700 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.3% of the company's stock are sold short. View Eyegate Pharmaceuticals' Current Options Chain.

Who are some of Eyegate Pharmaceuticals' key competitors?

What other stocks do shareholders of Eyegate Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyegate Pharmaceuticals investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), Novavax (NVAX), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), Arca Biopharma (ABIO), SCYNEXIS (SCYX) and Synergy Pharmaceuticals (SGYP).

Who are Eyegate Pharmaceuticals' key executives?

Eyegate Pharmaceuticals' management team includes the following people:
  • Mr. Stephen From, Pres, CEO & Director (Age 56)
  • Dr. Barbara M. Wirostko, Chief Medical Officer (Age 53)
  • Mr. Michael P. Manzo, VP of Engineering (Age 60)
  • Ms. Sarah Romano, Chief Financial Officer
  • Dr. MaryJane Rafii Ph.D., Consultant

When did Eyegate Pharmaceuticals IPO?

(EYEG) raised $5 million in an IPO on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.

What is Eyegate Pharmaceuticals' stock symbol?

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

How do I buy shares of Eyegate Pharmaceuticals?

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eyegate Pharmaceuticals' stock price today?

One share of EYEG stock can currently be purchased for approximately $5.10.

How big of a company is Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals has a market capitalization of $23.61 million and generates $2.69 million in revenue each year. The specialty pharmaceutical company earns $-7,100,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Eyegate Pharmaceuticals employs 11 workers across the globe.

What is Eyegate Pharmaceuticals' official website?

The official website for Eyegate Pharmaceuticals is www.eyegatepharma.com.

How can I contact Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.